Voluntary announcement - SYS6077 injection obtains clinical trial approval in China
Filed with HKEX · Stock code 1093 · · 2 pages · English
Summary by 6ix AI
This product is a therapeutic messenger RNA cancer vaccine developed using the company's nano-delivery technology platform. The approval represents a significant advancement in mRNA technology and tumor immunity for the company. Clinical studies will assess the safety, immunogenicity, and preliminary anti-tumor activity of the product in patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/voluntary-announcement-sys6077-injection-obtains-clinical-trial-approval-in-china
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - phase III clinical trial of becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations achieves positive topline results
- Voluntary announcement - phase III clinical trial of docetaxel for injection (albumin-bound) (HB1801) for the treatment of advanced breast cancer officially initiated in china
- Notification letter to shareholder and change request form
- Notification letter to non-registered holder and request form
- Letter to new registered shareholders and reply form
Later from CSPC Pharmaceutical
- Voluntary announcement - recombinant herpes zoster vaccine (SYS6052) obtains clinical trial approval in the U.S.
- Voluntary announcement - Phase Ib clinical trial of JMT206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in China
- Voluntary announcement - results of phase III clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - latest updates from 8 clinical trials to be presented at the ESMO congress 2026
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical